U.S. FDA Issues Untitled Letter To Australia's CSL Biotherapies For GMP Deviations For Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - U.S. FDA's Center for Biologics issued an Untitled Letter June 24 to CSL Biotherapies for deviations from current good manufacturing practices at its manufacturing plant in the Australian state of Victoria
You may also be interested in...
Australia's CSL Slapped With U.S. FDA Warning Letter Over Flu Vaccine
U.S. FDA's Center for Biologics Evaluation and Research slapped CSL Biotherapies with a warning letter June 15 for significant objectionable conditions related to current good manufacturing practices at its Victoria, Australia, manufacturing plant
Australia's CSL Slapped With U.S. FDA Warning Letter Over Flu Vaccine
U.S. FDA's Center for Biologics Evaluation and Research slapped CSL Biotherapies with a warning letter June 15 for significant objectionable conditions related to current good manufacturing practices at its Victoria, Australia, manufacturing plant
CSL Bullish on Immunoglobulins, Bearish On Plasma Pricing
TOKYO - CSL closed its 2010 fiscal year with a mixed bag of results. From gains in its plasma portfolio to disappointments in Gardasil and influenza vaccines, the Melbourne, Australia-based company's 2011 outlook is a combination of caveats and prospects